04/16/2019 | Press release | Distributed by Public on 04/16/2019 02:40
Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) announced the pricing of an underwritten public offering of 4,500,000 shares of its common stock at a public offering price of $17.50 per share. The gross proceeds to Rocket from the offering are expected to be $78,750,000, before deducting the underwriting discounts and commissions and other offering expenses. Rocket has granted the underwriters a 30-day option to purchase up to an additional 675,000 shares of its common stock.
All the shares in the offering are to be sold by Rocket. The offering is expected to close on or about April 18, 2019, subject to satisfaction of customary closing conditions. Rocket intends to use the net proceeds from this offering to further fund the development of its pipeline of gene therapies for rare diseases, to accelerate the buildout of in-house manufacturing capabilities, and for general corporate purposes.
SVB Leerink, Evercore ISI and William Blair are acting as the joint-bookrunning managers and Oppenheimer & Co. is acting as lead manager for the public offering.